

Field Name	Field Description
Prior Authorization Group Description	Pompe Disease Agents
Drugs	Lumizyme (alglucosidase alfa) Nexviazyme (avalglucosidase alfa-ngpt) injection Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	According to FDA approved prescribing information
Prescriber Restrictions	Prescribed by, or in consultation with, a specialist in the treatment of Pompe disease, such as a genetic or metabolic specialist, neurologist, cardiologist, or pediatrician.
Coverage Duration	If all of the criteria are met, the request will be approved for 12 months.
Other Criteria	<u>Initial Authorization:</u> For infantile onset Pompe Disease (Lumizyme only): • Patient has a diagnosis of infantile-onset Pompe Disease, confirmed by one of the following: ○ Enzyme assay showing a deficiency of acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle ○ Genetic testing showing a mutation in the GAA gene • Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request) • Requested regimen will not be used in combination with other enzyme replacement therapies For late onset Pompe Disease (Lumizyme, Nexviazyme, or Pombiliti + Opfolda): • Patient has a diagnosis of late-onset (non-infantile) Pompe Disease, confirmed by one of the following: ○ Enzyme assay showing a deficiency of acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle ○ Genetic testing showing a mutation in the GAA gene • Documentation patient has measurable signs or symptoms of Pompe disease • Results of a baseline 6-minute walk test (6MWT) and percent-predicted forced vital capacity (FVC) are provided (not required for patients who are not old enough to walk) • Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request)

Revision/Review Date: 2/2025	• Requested regimen will not be used in combination with other enzyme replacement therapies (Exception: Pombiliti + Opfolda are to be used together) • Additionally for Nexviazyme: Patients < 30 kg must provide documentation of a trial and therapy failure of, or a medical reason why Lumizyme may not be used. • Additionally for Pombiliti + Opfolda: Patient must have trial and failure of another enzyme therapy (Lumizyme or Nexviazyme) <u>Re-Authorization:</u> • Documentation or provider attestation of positive clinical response to therapy ○ Infantile onset: provider attestation of member benefit ○ Late onset: improvement, stabilization, or slowing of progression of percent-predicted FVC and/or 6MWT • Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request) • Requested regimen will not be used in combination with other enzyme replacement therapies (Exception: Pombiliti + Opfolda are to be used together) Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.
---	---